MX2019001344A - Composicion inyectable estable de ibuprofeno. - Google Patents
Composicion inyectable estable de ibuprofeno.Info
- Publication number
- MX2019001344A MX2019001344A MX2019001344A MX2019001344A MX2019001344A MX 2019001344 A MX2019001344 A MX 2019001344A MX 2019001344 A MX2019001344 A MX 2019001344A MX 2019001344 A MX2019001344 A MX 2019001344A MX 2019001344 A MX2019001344 A MX 2019001344A
- Authority
- MX
- Mexico
- Prior art keywords
- ibuprofen
- composition
- injectable composition
- stable injectable
- arginine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a una composición para la formulación inyectable, la composición que comprende: - Una solución acuosa de ibuprofeno y arginina con una relación molar de ibuprofeno: arginina comprendida entre 1:1.1 y 1:2.1; - Una solución acuosa de un compuesto diurético que comprende entre un 3.9 % y un 4.35 % p/v del compuesto diurético. La presente invención también se refiere a una composición farmacéutica que comprende dicha composición y al uso de dicha composición y dicha composición farmacéutica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PK4682016 | 2016-08-02 | ||
| PCT/IB2017/054556 WO2018025128A1 (en) | 2016-08-02 | 2017-07-27 | Stable ibuprofen injectable composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019001344A true MX2019001344A (es) | 2019-08-29 |
Family
ID=59699972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019001344A MX2019001344A (es) | 2016-08-02 | 2017-07-27 | Composicion inyectable estable de ibuprofeno. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11541024B2 (es) |
| EP (1) | EP3493788B1 (es) |
| JP (2) | JP7386080B2 (es) |
| KR (1) | KR102387287B1 (es) |
| CN (1) | CN109843266B (es) |
| AU (1) | AU2017307313B2 (es) |
| BR (1) | BR112019002058A2 (es) |
| CA (1) | CA3032493C (es) |
| MX (1) | MX2019001344A (es) |
| WO (1) | WO2018025128A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3893840B1 (en) * | 2018-12-14 | 2025-07-09 | Fresenius Kabi Austria GmbH | Pharmaceutical compositions for parenteral administration comprising ibuprofen and a phosphate buffer |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3932829C1 (es) * | 1989-09-30 | 1991-05-02 | Ciba-Geigy Ag, Basel, Ch | |
| US6887462B2 (en) | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
| AU2002224475B2 (en) * | 2001-11-02 | 2008-01-17 | Cumberland Pharmaceuticals Inc. | Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid |
| EP1761234B1 (de) * | 2004-06-21 | 2013-08-14 | Basf Se | Wässrige zubereitungen enthaltend ein wasserlösliches oder wasserdispergierbares copolymer, das wenigstens ein monomer mit einem protonierbaren stickstoffatom enthält |
| RU2007124933A (ru) | 2005-01-28 | 2009-03-10 | Вайет (Us) | Стабилизированные жидкие полипептидные составы |
| US7785624B2 (en) | 2006-03-02 | 2010-08-31 | Inspire Pharmaceuticals, Inc. | Pharmaceutical latrunculin formulations |
| CN101069681A (zh) * | 2006-05-10 | 2007-11-14 | 汪洪湖 | 含有布洛芬的注射剂及其制备方法 |
| WO2008025560A1 (en) * | 2006-09-01 | 2008-03-06 | Pari Pharma Gmbh | Methods for taste masking of nebulised compositions for nasal and pulmonary inhalation therapy |
| CN102335114B (zh) * | 2010-07-23 | 2015-07-15 | 重庆医药工业研究院有限责任公司 | 一种稳定的布洛芬精氨酸注射剂及其制备方法 |
| PL2636406T3 (pl) * | 2012-02-20 | 2016-01-29 | Pharmaceutical Solutions Ind Ltd | Ibuprofen do wlewu dożylnego |
| ES2422563B1 (es) * | 2012-03-08 | 2014-06-10 | Farmalider S.A. | Composición farmacéutica inyectable de ibuprofeno y arginina, su procedimiento de preparación, forma de dosificación unitaria y utilización de la misma |
| US20150208705A1 (en) * | 2012-08-09 | 2015-07-30 | Nestec S.A. | Anthocyanin colouring composition |
| CN103284985A (zh) * | 2013-05-20 | 2013-09-11 | 北京阜康仁生物制药科技有限公司 | 稳定的(S)-α-甲基-4-（2-甲基丙基）苯乙酸药物组合物 |
| CN103301118A (zh) * | 2013-06-27 | 2013-09-18 | 海南卫康制药(潜山)有限公司 | 注射用精氨酸布洛芬组合物 |
| WO2016008546A1 (en) * | 2014-07-18 | 2016-01-21 | Everbright Pharmaceuticals S.A.R.L. | Aqueous formulation comprising paracetamol and ibuprofen |
-
2017
- 2017-07-27 CN CN201780054476.5A patent/CN109843266B/zh active Active
- 2017-07-27 WO PCT/IB2017/054556 patent/WO2018025128A1/en not_active Ceased
- 2017-07-27 AU AU2017307313A patent/AU2017307313B2/en active Active
- 2017-07-27 EP EP17757569.3A patent/EP3493788B1/en active Active
- 2017-07-27 CA CA3032493A patent/CA3032493C/en active Active
- 2017-07-27 KR KR1020197005758A patent/KR102387287B1/ko active Active
- 2017-07-27 MX MX2019001344A patent/MX2019001344A/es unknown
- 2017-07-27 BR BR112019002058-6A patent/BR112019002058A2/pt not_active Application Discontinuation
- 2017-07-27 US US16/322,569 patent/US11541024B2/en active Active
- 2017-07-27 JP JP2019506368A patent/JP7386080B2/ja active Active
-
2022
- 2022-03-31 JP JP2022057943A patent/JP7542028B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022089867A (ja) | 2022-06-16 |
| CN109843266A (zh) | 2019-06-04 |
| KR20190062385A (ko) | 2019-06-05 |
| CA3032493C (en) | 2022-07-05 |
| AU2017307313A1 (en) | 2019-02-28 |
| EP3493788A1 (en) | 2019-06-12 |
| JP7386080B2 (ja) | 2023-11-24 |
| KR102387287B1 (ko) | 2022-04-14 |
| US20190183823A1 (en) | 2019-06-20 |
| JP2019523292A (ja) | 2019-08-22 |
| WO2018025128A1 (en) | 2018-02-08 |
| JP7542028B2 (ja) | 2024-08-29 |
| BR112019002058A2 (pt) | 2019-05-07 |
| US11541024B2 (en) | 2023-01-03 |
| AU2017307313B2 (en) | 2021-09-09 |
| CA3032493A1 (en) | 2018-02-08 |
| CN109843266B (zh) | 2023-08-11 |
| EP3493788B1 (en) | 2025-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023001909A1 (es) | Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo | |
| CL2019000477A1 (es) | Un esteroide 19 nor-c21-n-pirazolilo c3,3- disustituido cristalino. | |
| CL2015002330A1 (es) | Análogo de insulina novedoso y su uso. | |
| ECSP19021223A (es) | Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo | |
| MX2016015636A (es) | Formulaciones cannabinoides estables. | |
| CL2016001547A1 (es) | Composiciones para el cuidado oral | |
| CU20170172A7 (es) | 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos | |
| DOP2017000137A (es) | Benzamidas sustituidas con 1,3tiazol2ilo. | |
| CL2017000984A1 (es) | Reducción de la viscosidad de formulaciones farmacéuticas | |
| BR112018075140A2 (pt) | composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8 | |
| AR098168A1 (es) | Formulación estable de insulina glulisina | |
| CL2018000249A1 (es) | Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h | |
| CL2017001483A1 (es) | Formulación de relación fija de insulina glargina/lixisenatida | |
| CO2018007810A2 (es) | Formulación líquida estable de gonadotropina | |
| MX384877B (es) | Composiciones de éster de colina de ácido lipoico y métodos de uso. | |
| CO2017005968A2 (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
| CL2020002101A1 (es) | Formulaciones de liberación sostenida de ácido bempedoico. | |
| CL2016000027A1 (es) | Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán. | |
| ECSP17015154A (es) | Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo | |
| CL2019000099A1 (es) | Factor vii de coagulación de larga duración y métodos para producir el mismo. | |
| MX2018015965A (es) | Composicion de dos componentes. | |
| MX369778B (es) | Potenciadores de solubilidad del agua a base de glucogeno. | |
| MX374618B (es) | Ésteres sulfatados de ácidos oligohidroxicarboxílicos, y uso de los mismos. | |
| MX2019001344A (es) | Composicion inyectable estable de ibuprofeno. | |
| AR092585A1 (es) | Accesorio para un recipiente |